MedPath

Sorafenib

Generic Name
Sorafenib
Brand Names
Nexavar, Sorafenib Accord
Drug Type
Small Molecule
Chemical Formula
C21H16ClF3N4O3
CAS Number
284461-73-0
Unique Ingredient Identifier
9ZOQ3TZI87
Background

Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.

Indication

Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.

Associated Conditions
Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
Clinical Trials
Related News

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Phase 3
Recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Drug: IBI310
First Posted Date
2021-01-22
Last Posted Date
2022-09-19
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
490
Registration Number
NCT04720716
Locations
🇨🇳

Fudan Universtiy Zhongshan Hospital, Shanghai, Shanghai, China

Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone

Phase 2
Completed
Conditions
Hepatitis C
Hepatocellular Carcinoma
Hepatitis B
Interventions
First Posted Date
2021-01-15
Last Posted Date
2025-03-06
Lead Sponsor
Mina Alpha Limited
Target Recruit Count
8
Registration Number
NCT04710641
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇸🇬

National University Hospital Singapore, Singapore, Singapore

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma with PVTT

Phase 3
Terminated
Conditions
Radiotherapy
Toripalimab
Sorafenib
Advanced Hepatocellular Carcinoma
Interventions
Other: Radiotherapy plus Toripalimab
First Posted Date
2021-01-14
Last Posted Date
2025-02-26
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
36
Registration Number
NCT04709380
Locations
🇨🇳

Bo Chen, Beijing, Beijing, China

Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia

Phase 2
Conditions
Acute Leukemia
Relapse
Hematopoietic Stem Cell Transplantation
Interventions
First Posted Date
2020-12-19
Last Posted Date
2021-11-08
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
346
Registration Number
NCT04674345
Locations
🇨🇳

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Phase 2
Active, not recruiting
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2020-09-23
Last Posted Date
2024-02-01
Lead Sponsor
Sinocelltech Ltd.
Target Recruit Count
405
Registration Number
NCT04560894
Locations
🇨🇳

307 Hospital of PLA, Beijing, Beijing, China

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma

Completed
Conditions
Hepatocellular Carcinoma
Interventions
Device: Radiofrequency ablation
Drug: Trance-arterial chemoembolization
Procedure: Liver resection
Combination Product: Combined radiofrequency ablation + percutaneous ethanol injection
Drug: Systemic chemotherapy
Dietary Supplement: Viscum
Drug: Symptomatic treatment
First Posted Date
2020-09-17
Last Posted Date
2020-09-17
Lead Sponsor
Sohag University
Target Recruit Count
407
Registration Number
NCT04553458

A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

Phase 3
Withdrawn
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
First Posted Date
2020-07-10
Last Posted Date
2022-05-05
Lead Sponsor
Shanghai Henlius Biotech
Registration Number
NCT04465734
Locations
🇨🇳

Ethics committee of zhongshan hospital affiliated to fudan university, Shanghai, China

SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT

Phase 3
Recruiting
Conditions
Unresectable Hepatocellular Carcinoma
Portal Vein Thrombosis
Interventions
Radiation: SBRT+TACE+Sorafenib
First Posted Date
2020-05-14
Last Posted Date
2023-02-16
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
54
Registration Number
NCT04387695
Locations
🇨🇳

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Phase 3
Active, not recruiting
Conditions
Advanced Hepatocellular Carcinoma (HCC)
Interventions
Drug: AK105 Injection
First Posted Date
2020-04-14
Last Posted Date
2025-02-20
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Target Recruit Count
648
Registration Number
NCT04344158
Locations
🇨🇳

The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

🇨🇳

The Second Hospital of Nanjing, Nanjing, Jiangsu, China

🇨🇳

Shanxi Provinaial Cancer Hospital, Taiyuan, Shanxi, China

and more 78 locations

AflacLL1901 (CHOA-AML)

Phase 2
Terminated
Conditions
Acute Myeloid Leukemia
AML, Childhood
Interventions
Procedure: Stem cell transplantation (SCT)
First Posted Date
2020-03-30
Last Posted Date
2022-06-15
Lead Sponsor
Emory University
Target Recruit Count
8
Registration Number
NCT04326439
Locations
🇺🇸

Egleston Hospital, Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy